Navigation Links
Almac Discovery and Queen's launch £13M cancer drug discovery partnership
Date:9/4/2013

A new 13 million partnership to accelerate cancer-focused drug discovery in Northern Ireland has been launched by Enterprise Minister Arlene Foster MLA.

As part of the project, Queen's and Almac Discovery have announced the scheduling of a phase one clinical trial for ovarian cancer, involving the first novel cancer drug fully developed in Northern Ireland.

Involving up to 60 ovarian cancer patients, the drug being trialled has been created as a result of an earlier collaboration between Almac Discovery and Professor Tracy Robson from the School of Pharmacy at Queen's.

Explaining about the trial, Professor Robson said: "This latest trial involves a new treatment for cancer known as ALM201, which rather than attacking tumours directly, prevents the growth of new blood vessels in tumours, starving them of oxygen and nutrients and thereby preventing their growth. It targets tumours by an entirely different pathway to those treatments currently approved."

Alan Armstrong, CEO of Almac added: "Bringing new treatments to patients is a complex process. The announcement today of a new clinical trial, which is the result of a previous partnership between Almac and Queen's School of Pharmacy, is a timely illustration of how collaboration between the University and industry is already creating novel approaches to cancer therapy which have a very real chance of helping patients."

At today's event, Enterprise Minister Arlene Foster, said: "This significant investment in research and development will enhance collaboration between academia and industry. This will ensure the investment is maximised, that research is effectively commercialised and that ultimately, enhanced treatment solutions are made available to cancer patients.

"The fact that Almac and Queen's are engaged in such ground-breaking research here in Northern Ireland is something that we should be extremely proud of. It will reinforce our position as a leader in research and development for the health and life sciences sector."

It was also announced today that a new CCRCB/Almac Discovery joint programme in Cancer Drug Discovery will bring researchers from Queen's University Belfast's Centre for Cancer Research and Cell Biology (CCRCB) and scientists from Almac Discovery together to translate research discoveries into treatments for patients.

The two projects represent a total investment of 13M, with 7 million of support offered by Invest Northern Ireland, which includes part funding from the European Regional Development Fund.

As a result of the joint programme, 17 scientists from Almac Discovery have been seconded to Queen's CCRCB in an industry led venture. The discovery team will work to identify parts of tumours which are susceptible to treatment by cancer drugs and to then develop the new drugs to target them.

The partnership will also enable new approaches to selecting those patients who will be most likely to respond to the new drugs, and to create the technologies needed to deliver the drugs directly to the tumour site in the patient.

The new discovery programme is being led by Professor Tim Harrison, Vice President of Discovery Chemistry with Almac Discovery. As part of this partnership, Professor Harrison has been appointed McClay Chair of Medicinal Chemistry at Queen's for the next three years.

Commenting on the new partnership, he said: "While Almac Discovery and Queen's have already been successfully collaborating for a number of years, this exciting new programme is bringing together for the first time, under one roof, some of our most talented scientists. As a result we expect to see an increase in both the breadth of drug targets we are able to identify and a subsequent increase in the development of potential therapeutics for patients."


'/>"/>

Contact: Lisa McElroy
lisa.mcelroy@qub.ac.uk
44-028-909-75384
Queen's University Belfast
Source:Eurekalert

Related medicine news :

1. Shapeshifting computer program will open up drug discovery for tricky disease targets
2. Vaginal Mesh Lawsuits Proceed Against Ethicon, as Bernstein Liebhard LLP Notes Order for Discovery Conferences in Federal Ethicon Litigation
3. Transvaginal Mesh Multidistrict Litigation Update: Court Issues New Pretrial Order that Moves Ethicon Inc.’s Discovery Forward, Notes Parker Waichman
4. ChanTest Announces Third User Meeting: Partnerships in Drug Discovery
5. Voices Against Brain Cancer Comments on Discovery of Nano Drug That May Aid in Treatment of Brain Tumors
6. An important discovery at the Montreal Heart Institute: A new approach to treat the most common heart valve disease in Western countries
7. Voices Against Brain Cancer Comments on Discovery of a Cause of Resistance to Therapy in Cases of Brain Cancer
8. Voices Against Brain Cancer Comments on Recent Discovery in Ongoing Brain Cancer Research
9. MessageSolution Showcases its Cloud Archiving and eDiscovery Platform at HostingCon 2013, Introduces its Enhanced MSP Partner Program
10. The Discovery House Supports Cancer Awareness and Cure
11. Laboratory Automation Market: 2017 Equipment & Software, Drug Discovery, Clinical Diagnostics, Genomics & Proteomics Analysis in New Research Reports at RnRMarketResearch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... Grants Pass, OR (PRWEB) , ... April 28, ... ... Adetutu Ijose, http://www.foodsthathealdaily.com , http://www.wiredlifesolutions.com , “Computers are everywhere and ... Kleyne Hour Power of Water, Global Climate Change and Your Health on Voice ...
(Date:4/28/2017)... ... April 28, 2017 , ... Datta Endoscopic Back ... joined the revolutionary endoscopic practice under Dr. Datta. Patel is a Board Certified ... The patented, revolutionary eDiscSculpt Technique created and used by Datta Endoscopic is unlike ...
(Date:4/28/2017)... National Harbor, Md. (PRWEB) , ... April 28, ... ... Urgent Care Association of America (UCAOA) and College of Urgent Care Medicine will ... Momentum 2017 workshops, sessions and speakers will help those in the industry adapt ...
(Date:4/28/2017)... ... 2017 , ... Bill Howe started his sewer and drain company in 1980 ... joined the team, the Bill Howe brand was born and they began cultivating their ... back to the San Diego community in which they worked, lived and were raising ...
(Date:4/28/2017)... CITY, UTAH (PRWEB) , ... April 28, 2017 ... ... as Account Manager for the North East region. Côté has 20+ years of ... consulting. Prior to Phytomer, Côté worked with an array of high-end cosmetic brands, ...
Breaking Medicine News(10 mins):
(Date:4/24/2017)... 2017 SW Safety Solutions, Inc., the industry,s ... the release of the latest advancement in workplace single-use ... of leading edge nitrile glove technology features SW,s patent ... tactile grip on wet and oily surfaces and the ... and a suite of other advanced SW technologies, the ...
(Date:4/20/2017)... 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), a ... Urology, Uro/Gyn and Gynecology markets with innovative and ... joined the Company as Senior Vice President, Marketing ... Mr. Keswani will report directly to Darin ... organization is delighted that Ash has joined the ...
(Date:4/20/2017)... April 20, 2017 Research and ... Biosimilar Pipeline and Market Prospects: Addressing Production Complexities Through ... their offering. ... "Global Biosimilar Pipeline and Market Prospects: Overcoming Production ... an in-depth assessment of the current trends in the ...
Breaking Medicine Technology: